Clinical and Molecular Hepatology (Clin Mol Hepatol, CMH)

Hironori Koga, Hideki Iwamoto, Hiroyuki Suzuki, Shigeo Shimose, Masahito Nakano, Takumi Kawaguchi

Clin Mol Hepatol. 2023;29(2):242-251. Published online March 20, 2023

DOI: https://doi.org/10.3350/cmh.2023.0102

View: 1285 Download: 130

Hideki Iwamoto, Shigeo Shimose, Takashi Niizeki, Hironori Koga, Takuji Torimura

Clin Mol Hepatol. 2022;28(3):575-579. Published online April 21, 2022

DOI: https://doi.org/10.3350/cmh.2022.0047

View: 2132 Download: 183 Citations: 3

Takuji Torimura, Hideki Iwamoto

Clin Mol Hepatol. 2021;27(2):236-245. Published online December 3, 2020

DOI: https://doi.org/10.3350/cmh.2020.0204

View: 6266 Download: 312 Citations: 28

Hideki Iwamoto, Shigeo Shimose, Tomotake Shirono, Takashi Niizeki, Takumi Kawaguchi

Received November 9, 2022 Accepted February 9, 2023

DOI: https://doi.org/10.3350/cmh.2022.0391 [Epub ahead of print]

View: 775 Download: 152 Citations: 2

1 |

Viewed By 4201	Hepatocellular carcinoma surveillance in patients with non-alcoholic fatty liver disease
Viewed By 2797	Pathogenesis and treatment of non-alcoholic steatohepatitis and its fibrosis
Viewed By 2557	Recent updates on the management of autoimmune hepatitis
Viewed By 2523	Management of refractory ascites
Viewed By 2478	The independent effect of exercise on biopsy proven non-alcoholic fatty liver disease: A systematic review

Cited By 100	KASL clinical practice guidelines: Management of nonalcoholic fatty liver disease
Cited By 44	From nonalcoholic fatty liver disease to metabolic-associated fatty liver disease: Big wave or ripple?
Cited By 42	Lactobacillus attenuates progression of nonalcoholic fatty liver disease by lowering cholesterol and steatosis
Cited By 40	Obesity and the risk of primary liver cancer: A systematic review and meta-analysis
Cited By 38	The development of mesenchymal stem cell therapy in the present, and the perspective of cell-free therapy in the future

Search